Literature DB >> 28807909

Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection.

Robert T Schooley1, Biswajit Biswas2,3, Jason J Gill4,5, Adriana Hernandez-Morales6, Jacob Lancaster5, Lauren Lessor5, Jeremy J Barr7,8, Sharon L Reed9,10, Forest Rohwer7, Sean Benler7, Anca M Segall7, Randy Taplitz9, Davey M Smith9, Kim Kerr9, Monika Kumaraswamy9, Victor Nizet11,12, Leo Lin11, Melanie D McCauley9, Steffanie A Strathdee9, Constance A Benson9, Robert K Pope13, Brian M Leroux13, Andrew C Picel14, Alfred J Mateczun2, Katherine E Cilwa15, James M Regeimbal2, Luis A Estrella2, David M Wolfe2, Matthew S Henry2,3, Javier Quinones2,3, Scott Salka16, Kimberly A Bishop-Lilly2,3, Ry Young5,6, Theron Hamilton2.   

Abstract

Widespread antibiotic use in clinical medicine and the livestock industry has contributed to the global spread of multidrug-resistant (MDR) bacterial pathogens, including Acinetobacter baumannii We report on a method used to produce a personalized bacteriophage-based therapeutic treatment for a 68-year-old diabetic patient with necrotizing pancreatitis complicated by an MDR A. baumannii infection. Despite multiple antibiotic courses and efforts at percutaneous drainage of a pancreatic pseudocyst, the patient deteriorated over a 4-month period. In the absence of effective antibiotics, two laboratories identified nine different bacteriophages with lytic activity for an A. baumannii isolate from the patient. Administration of these bacteriophages intravenously and percutaneously into the abscess cavities was associated with reversal of the patient's downward clinical trajectory, clearance of the A. baumannii infection, and a return to health. The outcome of this case suggests that the methods described here for the production of bacteriophage therapeutics could be applied to similar cases and that more concerted efforts to investigate the use of therapeutic bacteriophages for MDR bacterial infections are warranted.

Entities:  

Keywords:  Acinetobacter; bacteriophage therapy; multidrug resistance

Mesh:

Substances:

Year:  2017        PMID: 28807909      PMCID: PMC5610518          DOI: 10.1128/AAC.00954-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.

Authors:  Cesar A Arias; Barbara E Murray
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

3.  Phages, Fitness, Virulence, and Synergy: A Novel Approach for the Therapy of Infections Caused by Pseudomonas aeruginosa.

Authors:  Charles W Stratton
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

4.  Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium.

Authors:  Biswajit Biswas; Sankar Adhya; Paul Washart; Brian Paul; Andrei N Trostel; Bradford Powell; Richard Carlton; Carl R Merril
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh.

Authors:  Shafiqul Alam Sarker; Bernard Berger; Ying Deng; Silas Kieser; Francis Foata; Deborah Moine; Patrick Descombes; Shamima Sultana; Sayeeda Huq; Pradip Kumar Bardhan; Valérie Vuillet; Fabienne Praplan; Harald Brüssow
Journal:  Environ Microbiol       Date:  2016-11-13       Impact factor: 5.491

Review 6.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

7.  Identification of Listeria monocytogenes determinants required for biofilm formation.

Authors:  Almaris N Alonso; Kyle J Perry; James M Regeimbal; Patrick M Regan; Darren E Higgins
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

8.  Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  PLoS Pathog       Date:  2015-02-13       Impact factor: 6.823

9.  The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams.

Authors:  Nicolas Dufour; Raphaëlle Delattre; Jean-Damien Ricard; Laurent Debarbieux
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

10.  Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.

Authors:  Frank Oechslin; Philippe Piccardi; Stefano Mancini; Jérôme Gabard; Philippe Moreillon; José M Entenza; Gregory Resch; Yok-Ai Que
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

View more
  277 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

Review 2.  The Lung Microbiome and Its Role in Pneumonia.

Authors:  Benjamin G Wu; Leopoldo N Segal
Journal:  Clin Chest Med       Date:  2018-12       Impact factor: 2.878

3.  Bacteriophage Resistance Alters Antibiotic-Mediated Intestinal Expansion of Enterococci.

Authors:  Anushila Chatterjee; Cydney N Johnson; Phat Luong; Karthik Hullahalli; Sara W McBride; Alyxandria M Schubert; Kelli L Palmer; Paul E Carlson; Breck A Duerkop
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

4.  A Dutch Case Report of Successful Treatment of Chronic Relapsing Urinary Tract Infection with Bacteriophages in a Renal Transplant Patient.

Authors:  Saskia Kuipers; Mike M Ruth; Mike Mientjes; Ruud G L de Sévaux; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

5.  Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018.

Authors:  David J Lemon; Matthew K Kay; James K Titus; April A Ford; Wen Chen; Nicholas J Hamlin; Yoon Y Hwang
Journal:  J Microbiol       Date:  2019-05-27       Impact factor: 3.422

6.  Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research: Personalized Infectious Disease Medicine for the Most Vulnerable At-Risk Patients.

Authors:  Austen L Terwilliger; Carmen Gu Liu; Sabrina I Green; Justin R Clark; Keiko C Salazar; Haroldo Hernandez Santos; Emmaline R Heckmann; Barbara W Trautner; Robert F Ramig; Anthony W Maresso
Journal:  Phage (New Rochelle)       Date:  2020-06-16

Review 7.  Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.

Authors:  Sabrina Royer; Aléxia Pinheiro Morais; Deivid William da Fonseca Batistão
Journal:  Arch Microbiol       Date:  2021-01-20       Impact factor: 2.552

8.  Coevolutionary phage training leads to greater bacterial suppression and delays the evolution of phage resistance.

Authors:  Joshua M Borin; Sarit Avrani; Jeffrey E Barrick; Katherine L Petrie; Justin R Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

9.  Current Management and Future Treatment of Alcoholic Hepatitis.

Authors:  Mack C Mitchell; Thomas Kerr; H Franklin Herlong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

10.  Decoding the molecular properties of mycobacteriophage D29 Holin provides insights into Holin engineering.

Authors:  Varun Rakeshbhai Bavda; Aditi Yadav; Vikas Jain
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.